Insulin Isophane Human/Insulin Regular Human

DEA Class; OTC

Common Brand Names; Humulin 70/30, Novolin 70/30

  • Antidiabetics, Insulins

A combination of regular insulin and intermediate-acting insulin (NPH insulin); fixed-ratio mixtures
Used for type 1 and type 2 diabetes mellitus
For type 2 diabetes, most commonly given twice daily

Indicated for the treatment of type 1 diabetes mellitus.

For the treatment of type 2 diabetes mellitus.

Hypoglycemia

Documented hypersensitivity reactions to product or excipients

Hypoglycemia

Insulin resistance

Lipodystrophy

Lipohypertrophy

Local allergic reaction

Hypokalemia

Localized cutaneous amyloidosis

Never share pen between patients even if needle is changed

Intermediate-acting insulin, do not use for circumstances that require rapid-acting insulin

Caution with decreased insulin requirements (eg, diarrhea, nausea/vomiting, malabsorption, hypothyroidism, renal impairment, hepatic impairment)

Caution with increased insulin requirements (eg, fever, hyperthyroidism, trauma, infection, surgery)

Thiazolidinediones are peroxisome proliferator-activated receptor (PPAR)-gamma agonists and can cause dose-related fluid retention, particularly when used in combination with insulin; fluid retention may lead to or exacerbate heart failure, monitor for signs and symptoms of heart failure and treat accordingly and consider discontinuing thiazolidinediones

Hypoglycemia may be life-threatening; increase frequency of blood glucose monitoring with changes to: insulin dosage, co-administered glucose lowering medications, meal pattern, physical activity; in patients with renal or hepatic impairment; and in patients with hypoglycemia unawareness

Severe, life-threatening, generalized allergy, hypersensitivity, including anaphylaxis, can occur; discontinue therapy, monitor, and treat if indicated

Available data from published studies over decades have not established association with human insulin use during pregnancy and major birth defects, miscarriage or adverse maternal or fetal Outcomes

Available data from published literature suggests that exogenous human insulin products, are transferred into human milk

Specific maximum dosage information is not available. Individualize dosage based on careful monitoring of blood glucose and other clinical parameters in all patient populations.

NPH, human insulin isophane rDNA origin/regular, human insulin rDNA origin

Insulin isophane human/insulin regular human

injectable suspension

  • (70 units/30 units)/mL

About the Author

You may also like these

0